Is the price fair?
What BIIB's price assumes
Biogen trades at 23.8× earnings against 27.4× for the median Drug Manufacturers - General name, cheaper than its own group.
23.8
Trailing P/E · Drug Manufacturers - General median 27.4 · cheaper than the typical name in its group
- Price / sales
- 2.74
Price / sales · as of 2026-Q1
- Free cash flow yield
- 8.3%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- −1.2%
Growth the price implies · The price pays for −1.2% free cash flow growth a year for a decade; the business has delivered +19% a year over the last three.
Details›
- EV / sales2026-Q1
- 3.03
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - General median P/E16 names
- 27.4
- Free cash flow, trailing twelve months
- $2.42B
- Market capitalisation
- $29.0B
- 3-year revenue growth
- −0.55%
- 3-year free cash flow growth
- +19%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $128.38 |
| Its own P/E history, median | $156.99 |
| Its own P/E history, upper quartile | $200.07 |
| 52-week range | $127.75 – $221.50 |
| Today | $221.12 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #12 of 16 by Smart Score